WebApr 13, 2024 · Within the company's R&D pipeline, KT-A112 is a gene therapy administered through intramuscular injection that produces insulin and glucokinase to treat type 1 and type 2 diabetes patients; KT ... WebParagon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors.
Catalent Completes Acquisition of Gene Therapy Leader Paragon ...
WebJul 16, 2024 · Paragon Gene Therapy will also provide process development for clinical supply of additional viral therapies in AveXis pipeline, Catalent added. Zolgensma won the … WebApr 24, 2024 · With gene therapy, genes are replaced, inactivated or introduced into cells—either outside or inside the body—to treat a disease. ... Earlier this month (April 2024), Catalent agreed to acquire Paragon Bioservices, a Baltimore, Maryland-based contract provider of viral vector development and manufacturing services for gene therapies, for … first choice gyldendal
Amicus Therapeutics & Catalent Biologics Enter Strategic …
WebApr 15, 2024 · Paragon aims to build strong client partnerships with the world’s best biotech and pharma companies, focusing on transformative technologies, including gene … WebParagon Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has two facilities in Baltimore, Maryland dedicated to process development through commercial manufacturing of most ... WebJan 10, 2024 · Paragon Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including adeno-associated virus (AAV) gene therapies, next-generation vaccines, and oncology immunotherapies. first choice group google